

University of Groningen

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit

ESMO-MCBS Working Group and Extended Working Group; Oosting, S. F.; Barriuso, J.; Bottomley, A.; Galotti, M.; Gyawali, B.; Kiesewetter, B.; Latino, N. J.; Martinelli, F.; Pe, M.

Published in:
Annals of Oncology

DOI:
[10.1016/j.annonc.2022.12.004](https://doi.org/10.1016/j.annonc.2022.12.004)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2023

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

ESMO-MCBS Working Group and Extended Working Group, Oosting, S. F., Barriuso, J., Bottomley, A., Galotti, M., Gyawali, B., Kiesewetter, B., Latino, N. J., Martinelli, F., Pe, M., Pentheroudakis, G., Roitberg, F., Vachon, H., de Vries, E. G. E., Piccart, M., & Cherny, N. I. (2023). Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit. *Annals of Oncology*, 34(4), 431-439. <https://doi.org/10.1016/j.annonc.2022.12.004>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

ORIGINAL ARTICLE

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit

S. F. Oosting^{1*}, J. Barriuso², A. Bottomley³, M. Galotti⁴, B. Gyawali^{5,6,7}, B. Kiewewetter⁸, N. J. Latino⁴, F. Martinelli³, M. Pe³, G. Pentheroudakis⁴, F. Roitberg^{9,10}, H. Vachon³, E. G. E. de Vries¹, M. Piccart^{11‡} & N. I. Cherny^{12‡}, on behalf of the ESMO-MCBS Working Group and Extended Working Group[†]

¹Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; ²The Christie NHS Foundation Trust and Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; ³Quality of Life Department, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; ⁴ESMO Head Office, Lugano, Switzerland; ⁵Departments of ⁵Oncology; ⁶Public Health Sciences, Queen's University, Kingston; ⁷Division of Cancer Care and Epidemiology, Queen's University, Kingston, Canada; ⁸Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria; ⁹WHO Cancer Management Consultant, Geneva, Switzerland; ¹⁰Hospital Sírio Libanês, São Paulo, Brazil; ¹¹Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium; ¹²Cancer Pain and Palliative Medicine Service, Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel



Available online 19 December 2022

Background: The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) has been developed to grade clinical benefit of cancer therapies. Improvement in quality of life (QoL) is considered relevant, especially in the non-curative setting. This is reflected by an upgrade of the preliminary ESMO-MCBS score if QoL is improved compared to the control arm or a downgrade if an improvement in progression-free survival is not paralleled by an improvement in QoL or overall survival. Given the importance of QoL for the final score, a need to ensure the robustness of QoL data was recognised.

Design: A checklist was created based on existing guidelines for QoL research. Field testing was carried out using clinical trials that either received an adjustment of the preliminary ESMO-MCBS score based on QoL or had QoL as the primary endpoint. Several rounds of revision and re-testing of the checklist were undertaken until a final consensus was reached.

Results: The final checklist consists of four items and can be applied if three prerequisites are met: (i) QoL is at least a secondary endpoint, (ii) evidence of reliability and validity of the instrument is provided, and (iii) a statistically and clinically significant improvement in QoL is observed. The four items on the checklist pertain to the (i) hypothesis, (ii) compliance and missing data, (iii) presentation of the results, and (iv) statistical and clinical relevance. Field testing revealed that a clear QoL hypothesis and correction for multiple testing were mostly lacking, while the main statistical method was always described.

Conclusions: Implementation of the ESMO-MCBS QoL checklist will facilitate objective and transparent decision making on QoL data within the ESMO-MCBS scoring process. Trials published until 1 January 2025 will have to meet the prerequisites and at least two items for crediting QoL benefit in the final ESMO-MCBS score. Trials published thereafter will have to meet all four items.

Key words: quality of life, checklist, guidelines, ESMO-MCBS

*Correspondence to: Dr Sjoukje F. Oosting, Department of Medical Oncology, University Medical Center Groningen, Hanzeplein 1, Groningen, 9700 RB, The Netherlands. Tel: +31-503612821

E-mail: s.oosting@umcg.nl (S. F. Oosting).

Twitter handle: @OostingSjoukje, @DrJorgeBarriuso, @andrewbottom0, @MartinaGalotti, @oncology_bg, @NicolaJaneLatin, @madeline_pe, @GPentheroudakis, @FroitbergM, @VriesElisabeth, @ChernyNathan

‡Co-last authors.

†The individual names of the members of the ESMO-MCBS Working Group and Extended Working Group who are not listed as authors are provided in [Supplementary Appendix 1](https://doi.org/10.1016/j.annonc.2022.12.004), available at <https://doi.org/10.1016/j.annonc.2022.12.004>.

0923-7534/© 2023 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

INTRODUCTION

In 2015 the European Society for Medical Oncology (ESMO) introduced the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS), a validated tool to stratify the magnitude of clinical benefit derived from therapeutic approaches in a standardised way.¹ With the rapid increase of new treatment options and expanding cancer care costs, the ESMO-MCBS can assist as a tool for health-technology assessment. Every new anticancer medicine that receives approval from the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) is graded and assigned a score, which is publicly available on the ESMO website.² The highest grades of the ESMO-MCBS in the curative setting are A and B and in the non-curative setting are 5 and 4; these indicate medicines with a substantial clinical benefit. In 2017, ESMO-MCBS version 1.1 was published, incorporating several revisions and the ability to score single-arm studies.³

The ESMO-MCBS is based on the concept that potential benefits of a new treatment are not only to live longer, reflected by improved overall survival (OS), or surrogates such as disease-free survival (DFS) or progression-free survival (PFS) when validated, but also to live better, reflected by improved quality of life (QoL) or reduced toxicity compared to the previous standard of care. There are different settings in which QoL can determine the final ESMO-MCBS score. For new adjuvant or potentially curative therapies the combination of non-inferior OS or DFS with improved QoL results in a grade B (form 1). New treatment approaches not likely to be curative with OS or PFS as the primary endpoint receive a preliminary score based on OS or PFS benefit and are credited with an upgrade of 1 point if QoL is improved (forms 2a and 2b). Scores generated on PFS may also be downgraded in cases where there is no survival advantage with mature data and where QoL evaluation has not demonstrated any significant and clinically meaningful benefit. Furthermore, in non-inferiority studies with non-curative treatment approaches that have toxicity or QoL as the primary endpoint a treatment option can receive a grade 4 if QoL is improved and OS or PFS is at least non-inferior to the previous standard of care and a grade 3 if there is improvement in some pre-specified symptoms but not in overall QoL (form 2c). Finally, for single-arm studies for orphan diseases or situations with a high unmet need, the preliminary score that is based on PFS or overall response rate can be upgraded by 1 point if there is an improvement in QoL (form 3).

ESMO-MCBS version 1.1 instructions on scoring QoL benefit are limited to the requirements that QoL should be a primary endpoint (form 2c) or secondary endpoint (forms 2a, 2b, and 3), that a validated scale should be used, and that the gain must be statistically significant.

Given the importance of QoL for the final ESMO-MCBS score, a need to ensure the reliability and validity of the QoL data was recognised. This article describes the development of a checklist to guarantee that QoL data meet

Table 1. Guiding principles for QoL evaluation using the ESMO-MCBS

1	QoL data provide important information regarding patient benefit.
2	For an ESMO-MCBS credit, QoL must be either primary or secondary endpoint (not exploratory).
3	QoL must be assessed with a validated ^a health-related QoL instrument.
4	ESMO-MCBS assumes adequate validity, reliability, and responsiveness of the overall/global QoL scale.
5	Improvement in individual domains without significant overall/global QoL benefit is not sufficient for ESMO-MCBS credit, except when this is pre-specified in a study using QoL as the primary endpoint.
6	Benefit can be demonstrated by either improved QoL or delayed deterioration in overall/global QoL.
7	Benefit must be statistically and clinically ^b significant.
8	In studies with PFS as the primary endpoint, failure to demonstrate benefit in mature OS and QoL indicates weak surrogacy and scores are downgraded.

ESMO-MCBS, European Society for Medical Oncology-Magnitude of Clinical Benefit Scale; OS, overall survival; PFS, progression-free survival; QoL, quality of life.

^aA validated QoL instrument is a QoL tool with robust peer-reviewed data supporting its validity, reliability, and responsiveness.⁷

^bA threshold for clinical significance must be defined upfront.

adequate methodological and reporting standards to justify an impact on ESMO-MCBS scoring.

METHODOLOGY

In July 2019, the ESMO-MCBS Working Group established a collaboration with the Quality of Life Department of the European Organisation for Research and Treatment of Cancer (EORTC) to address this challenge.

Guidelines on the use of patient-reported outcomes (PROs) have previously been established and focus on inclusion in study protocols (SPIRIT-PRO),⁴ reporting (CONSORT-PRO),⁵ and analysis (SISAQOL).⁶

Items from CONSORT-PRO, SPIRIT-PRO, and SISAQOL and guiding principles agreed upon by the ESMO-MCBS team (Table 1) served as a basis to create the initial 17-item checklist (Supplementary Table S1, available at <https://doi.org/10.1016/j.annonc.2022.12.004>). All clinical trials previously scored by the ESMO-MCBS Working Group that received an adjustment of the preliminary ESMO-MCBS score based on QoL as a secondary endpoint or had QoL as primary endpoint (up to August 2019, $n = 17$) were selected for field testing. If applicable, separate publications on QoL, identified on PubMed, and supplementary files and the study protocols available on the journals' websites were retrieved to extract information.⁷⁻³² Each clinical trial was evaluated independently for compliance with the checklist criteria by three or four members of the project group (JB, BG, BK, FM, SFO, FR, and HV). Project group members were excluded from reviewing clinical trial articles which they co-authored.

Based on the feedback received from reviewers from the first round of field testing, checklist items were rephrased for clarity (Supplementary Table S2, available at <https://doi.org/10.1016/j.annonc.2022.12.004>). For consistency, a second round of field testing was conducted using the revised

checklist. A reconciliation meeting took place between the reviewers and checklist items with a lack of agreement ($\leq 50\%$) among the members were highlighted and re-discussed, with the goal of resolving discrepancies in the evaluation. If no agreement was found, another independent reviewer was involved. Subsequently, the clinical trials were ranked based on the number of checklist criteria that were met.

By combining the most important checklist items, determined by consensus, a condensed five-item checklist was created (Supplementary Table S3, available at <https://doi.org/10.1016/j.annonc.2022.12.004>) with three prerequisites that have to be met before the checklist can be applied. With these prerequisites and the shortened checklist the evaluation process was repeated. For field testing purposes the checklist was completed also for trials that did not meet all three prerequisites. Finally, to optimise clarity and ease of use, the checklist was edited to a four-item checklist combining items 4 and 5 to indicate that the benefit must be both statistically significant and clinically meaningful, and the three prerequisites were reworded to specify that compliance rates must be high and to emphasise that overall/global QoL needs to be improved (Supplementary Appendix 2, available at <https://doi.org/10.1016/j.annonc.2022.12.004>). Figure 1 summarises the methodology process.

RESULTS

The 17 clinical trials in which QoL data influenced the final ESMO-MCBS score, published between 2004 and 2018, were evaluated. Only 1 study included QoL as the primary endpoint,²¹ 15 had received an upgrade of the preliminary ESMO-MCBS score based on QoL, and 1 was downgraded because an improvement in PFS did not translate into improvement in QoL or OS.⁹ Eight clinical trials had a separate publication on QoL,^{11,13,16,18,23,25,27,32} two of which were published in the same journal simultaneously with the primary study report.¹⁵⁻¹⁸ Six QoL papers were published in a different journal with a lower impact factor at the time of the publication (mean difference = 34 points) and a mean time interval of 21 months since the primary publication. The details of the 17 clinical trials are shown in Table 2.

The first checklist version with 17 items took between 30 and 75 min per trial to complete, including the time needed to retrieve additional publications, supplementary files, and protocols, where relevant. Compliance of the evaluated studies with the 17-item checklist version 2 is presented in Table 3. Four clinical trials met at least 12 out of 17 criteria,^{15,17,22,26} one of which met all 17.¹⁵ Three clinical trials met five or fewer criteria.^{8,28,29} The five-item checklist took on average 20 min to complete.

According to the final four-item checklist (Supplementary Appendix 2, available at <https://doi.org/10.1016/j.annonc.2022.12.004>, Table 4), 14 out of 17 clinical trials met all three prerequisites. For field testing, the checklist items were nevertheless scored for all trials. Compliance rates for

QoL assessment of 14 clinical trials with adequate compliance data varied between 85% and 99% at baseline and between 64% and $>95\%$ during follow-up, which was deemed adequate. For the remaining three clinical trials, the compliance rates were not reported or could not be assessed because of limited information. Two trials satisfied all four items, another 2 trials satisfied three out of four items, 3 trials met two out of four, and 10 trials fulfilled one or zero items.

DISCUSSION

Endpoints used in cancer research require clear objective definitions and standard approaches for evaluation and reporting. These are well developed for event-based outcomes such as OS, DFS, PFS, and overall response rate which uses Response Evaluation Criteria In Solid Tumors (RECIST). Similarly, standards for toxicity reporting are established with the universal application of the Common Terminology Criteria for Adverse Events (CTCAE). In contrast, measuring QoL outcomes in clinical trials is complex and less well defined. There are many instruments and different ways to analyse the QoL data. Guidelines have been developed in the past decade, starting with recommendations for reporting,⁵ followed by guidelines for incorporating QoL in study protocols,⁴ and standards for statistical analysis.⁶ However, there is no vigilance to ensure compliance to guidelines as a prerequisite to publication. Consequently, the methodological quality of QoL research is variable exposing QoL research to bias.

Since the results of QoL studies can substantially influence ESMO-MCBS scoring, the issue of methodological validity is important for the scale. For example, if a study receives a preliminary ESMO-MCBS grade 3, but a final grade 4 based on QoL, it crosses the threshold of having achieved substantial benefit for purposes of decisions on resource allocations, guidelines, and clinical decision making.

Starting with a comprehensive list and using a reductive approach, the ESMO-MCBS QoL team, together with EORTC team, have now developed a short four-item checklist to facilitate objective and transparent decision making on credentialing QoL studies for use in the ESMO-MCBS scoring. Applying this methodological screening tool, the ESMO-MCBS Working Group aims to ensure that QoL studies meet adequate methodological thresholds to justify the adjustment of the ESMO-MCBS score. An upgrade of the preliminary ESMO-MCBS score for QoL benefit requires that improvement in overall or global QoL is demonstrated when QoL is a secondary endpoint, either as improved QoL or delay in the deterioration of QoL. Overall or global QoL is derived from the summary score of a validated instrument in accordance with the specific guidelines for the application of the nominated scale. For example, using the EORTC 30-item Core Quality of Life Questionnaire (QLQ-C30), overall health-related QoL is derived from items 29 and 30.³³ The ESMO-MCBS QoL team recognises that improvement of disease-related symptoms is important for patients,




Figure 1. ESMO-MCBS QoL checklist methodology process. CONSORT-PRO, Consolidated Standards of Reporting Trials on Patient Reported Outcomes; ESMO-MCBS, European Society for Medical Oncology-Magnitude of Clinical Benefit Scale; QoL, quality of life; SISAQOL, Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data; SPIRIT-PRO, Standard Protocol Items Recommendations for Interventional Trials for Patient Reported Outcomes.

and that description of multiple QoL domains and other PRO measures is highly valuable to enhance understanding of the impact of new therapies. However, improving specific symptoms or one or more functional domains without a benefit in overall or global QoL is not considered

sufficient for an upgrade of the ESMO-MCBS score. Only form 2c of the ESMO-MCBS v1.1 does credit symptom improvement with a grade 3, if this is the pre-specified primary endpoint of the trial, and a valid symptom evaluation scale is used.

Trial characteristics	Clinical trials <i>n</i> (%)
Disease	
Non-small-cell lung cancer	7 (41)
Prostate cancer	3 (18)
Breast cancer	2 (12)
Renal cell carcinoma	2 (12)
Ovarian cancer	1 (6)
Pancreatic cancer	1 (6)
Melanoma	1 (6)
Intervention	
Targeted therapy	9 (53)
Antiangiogenic therapy	3 (18)
Chemotherapy	2 (12)
Hormonal therapy	1 (6)
Early palliative care	1 (6)
Radio-isotope	1 (6)
Preliminary ESMO-MCBS score	
1	1 (6)
2	2 (12)
3	11 (65)
4	3 (18)
Separate publication on QoL	
Yes	8 (47)
No	9 (53)
QoL was a	
Primary endpoint	1 (6)
Secondary endpoint	16 (94)
Number of QoL instruments per trial	
One	6 (35)
Two	6 (35)
Three	3 (18)
More than three	2 (12)
Number of trials using QoL instrument	
EORTC QLQ-C30	10 (59)
EQ-5D-5L	6 (35)
EORTC QLQ-LC13	6 (35)
FACT-P	3 (18)
FACT-G	1 (6)
FACT-L	1 (6)
LCSS	1 (6)
EORTC QLQ-BR23	1 (6)
EORTC QLQ-OV28	1 (6)
FACT-B	1 (6)
FKSI-DRS	1 (6)
FKSI-15	1 (6)
FOSI	1 (6)
Main QoL analysis	
Proportion with improvement	7 (41)
Change from baseline over time	6 (35)
Time to deterioration	3 (18)
Between treatment differences in mean scores	1 (6)

EORTC, European Organisation for Research and Treatment of Cancer; ESMO-MCBS, European Society for Medical Oncology-Magnitude of Clinical Benefit Scale; EQ-5D-5L, EuroQol 5-dimensional descriptive system, 5-level version; FACT, Functional Assessment of Cancer Therapy scale (G, general; B, breast cancer; L, lung cancer; P, prostate cancer); FKSI-DRS, Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease Related Symptoms; FKSI-15, 15-item Functional Assessment of Cancer Therapy-Kidney Symptom Index; FOSI, Functional Assessment of Cancer Therapy-Ovarian Symptoms Index; LCSS, Lung Cancer Symptom Scale; OS, overall survival; PFS, progression-free survival; QLQ-C30, 30-item Core Quality of Life Questionnaire (LC13, 13-item Lung Cancer module; BR23, 23-item BReast cancer module; OV28, 28-item OVarian cancer module); QoL, quality of life.

The development process of the checklist revealed common methodological shortcomings in QoL studies in cancer. Most of the trials lacked a clear statement of the primary hypothesis for QoL, and for some studies it was not clear whether QoL was a secondary or exploratory

Checklist item	Clinical trials scoring positive <i>n</i> (%)
1 Were the background and rationale for PRO assessment stated?	9 (53)
2 Were the chosen PRO domains clearly stated?	10 (59)
3 Were the timepoints of the PRO assessment clearly stated?	16 (94)
4 Was the direction of the expected change (for example, we expect an increase—or decrease—in pain) clearly stated?	1 (6)
5 Was evidence of PRO instrument validity and reliability provided, or cited if available?	16 (94)
6 Was the statistical approach for dealing with missing data explicitly stated?	10 (59)
7 Were the baseline compliance rates for each treatment arm reported?	12 (71)
8 Were the follow-up compliance rates for each treatment arm and each time point reported?	8 (47)
9 Was the primary statistical method for PRO analysis described?	17 (100)
10 Were baseline PRO values reported, either in a table or in the text?	10 (59)
11 Were baseline scores reported for each treatment arm?	10 (59)
12 Were the primary analyses (as specified in the hypotheses) carried out by original assigned groups?	1 (6)
13 As specified in the hypotheses, were results from relevant domain(s) and time point(s) reported with the estimated effect size and its precision (such as 95% confidence interval)?	1 (6)
14 If more than one scale or domain and/or more than one follow-up assessment was included in the primary analysis, was statistical correction used?	2 (12)
15 Were PRO-specific limitations and implications for generalizability and clinical practice described?	8 (47)
16 Were PRO data not simply reported but also interpreted (i.e. trying to explain the relationship) in relation to clinical outcomes?	12 (71)
17 Was a measure of clinical relevance (for example, minimal important difference) taken into account when interpreting results?	13 (76)

ESMO-MCBS, European Society of Medical Oncology-Magnitude of Clinical Benefit Scale; PRO, patient-reported outcome; QoL, quality of life.

^aSeventeen-item checklist version 2, provided in [Supplementary Table S2](https://doi.org/10.1016/j.annonc.2022.12.004), available at <https://doi.org/10.1016/j.annonc.2022.12.004>.

endpoint. Two clinical trials were excluded from this evaluation because the type of endpoint for QoL was described differently in separate reports of the same study.³⁴⁻³⁷ Frequently, more than one PRO instrument was used, and different types of analyses were reported, such as change from baseline and time to deterioration, and subdomains were analysed without a statistical correction for multiple comparisons. These findings are consistent with previous reports on the quality of PRO analysis and reporting in randomised controlled trials of cancer.^{38,39} We also observed that there were long delays between the primary

Table 4. Field testing results with the final four-item ESMO-MCBS QoL checklist

Trial details				Prerequisites			Checklist items				Overall score	Ref	
Medication	Treatment setting	Trial name	Reason to include	ESMO-MCBS score	(i) Primary or secondary endpoint	(ii) Valid and reliable instrument	(iii) Statistically and clinically significant improvement in overall/global QoL	(i) Clear hypothesis and methods	(ii) Compliance and missing data	(iii) Results	(iv) Statistical and clinical significance ^a	Number of positive items	
Bevacizumab	Recurrent platinum-resistant ovarian cancer	AURELIA	Upgrade based on QoL improvement	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	4	15,16
T-DM1	HER2-positive, unresectable locally advanced, or metastatic breast cancer previously treated with trastuzumab and a taxane	EMILIA	Upgrade based on QoL improvement	4	Yes	Yes	Yes	Yes	Yes	Yes	Yes	4	10,11
Palbociclib	Hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer previously treated with endocrine therapy	PALOMA-3	Upgrade based on QoL improvement	4	Yes	Yes	Yes	Yes	Yes	Yes	No	3	12
Palliative care	First-line stage IV NSCLC		QoL primary endpoint	4	Yes	Yes	Yes	Yes	Yes	Yes	No	3	21
Radium-223	Late-line castration-refractory prostate cancer	ALSYMPCA	Upgrade based on QoL improvement	5	Yes	Yes	Yes	No	Yes	NA	Yes	2	26
Enzalutamide	Second-line castration-refractory prostate cancer after docetaxel	AFFIRM	Upgrade based on QoL improvement	4	Yes	Yes	Yes	Yes	No	No	Yes	2	28
Docetaxel 3-weekly	Castration-refractory prostate cancer	TAX 327	Upgrade based on QoL improvement	3	Yes	Yes	Yes	Yes	No	Yes	No	2	29
FOLFIRINOX	First-line advanced or metastatic pancreatic cancer		Upgrade based on QoL improvement	5	Yes	Yes	Yes	Yes	No	NA	No	1	14
Afatinib	First-line EGFR TKI-naïve locally advanced or metastatic NSCLC with activating EGFR mutation	LUX-LUNG 3	Upgrade based on QoL improvement	4	Yes	Yes	Yes	No	Yes	NA	No	1	17,18
Ceritinib	First-line stage IIIB or IV ALK-rearranged non-squamous NSCLC	ASCEND-4	Upgrade based on QoL improvement	4	Yes	Yes	Yes	No	Yes	NA	No	1	7
Sunitinib	First-line metastatic RCC		Upgrade based on QoL improvement	4	Yes	Yes	Yes	No	Yes	NA	No	1	30,31
Afatinib	Squamous NSCLC progressing on or after platinum-based ChT	LUX-LUNG 8	Upgrade based on QoL improvement	2	Yes	Yes	Yes	No	Yes	NA	No	1	22
Crizotinib	First-line stage III or IV ALK-rearranged non-squamous NSCLC	PROFILE 1014	Upgrade based on QoL improvement	4	Yes	Yes	Yes	No	No	NA	No	0	20
Crizotinib	Second-line stage III or IV ALK-rearranged non-squamous NSCLC	PROFILE 1007	Upgrade based on QoL improvement	4	Yes	Yes	Yes	No	No	NA	No	0	19
Dabrafenib	First-line unresectable or metastatic melanoma with BRAF V600E mutation	BREAK-3	Upgrade based on QoL improvement	4	Yes	Yes	No	No	No	NA	No	0	24,25

Continued

Table 4. Continued

Trial details		Prerequisites		Checklist items				Overall score	Ref				
Medication	Treatment setting	Trial name	Reason to include	ESMO-MCBS score	(i) Primary or secondary endpoint	(ii) Valid and reliable instrument	(iii) Statistically and clinically significant improvement overall/global QoL	(i) Clear hypothesis and methods	(ii) Compliance and missing data	(iii) Results	(iv) Statistical and clinical significance ^a	Number of positive items	
Ceritinib	Stage IIIB or IV ALK-rearranged NSCLC previously treated with chemotherapy and crizotinib	ASCEND-5	Upgrade based on QoL improvement	4	Yes	No	Yes	No	No	NA	No	0	8
Tivozanib	First-line metastatic RCC or second line after progression on cytokine therapy	TIVO-1	Downgrade for lack of QoL improvement	1	Yes	Yes	No	No	No	NA	No	0	9

ChT, chemotherapy; ECOG score, Eastern Cooperative Oncology Group score; EGFR, epidermal growth factor receptor; ESMO-MCBS, European Society of Medical Oncology-Magnitude of Clinical Benefit Scale; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; NSCLC, non-small-cell lung cancer; QoL, quality of life; RCC, renal cell carcinoma; T-DM1, trastuzumab emtansine.

^aThe difference in the results for prerequisite 3 and checklist item 4 is caused by the fact that for a positive score on item 4, a positive answer on three questions is required: a clear description of primary statistical method, correction for multiplicity, and the use of a pre-defined threshold for clinical relevance.

publications and separate publications on QoL data. If QoL was a secondary endpoint but has not been published, this will be annotated on the ESMO-MCBS Scorecard.

The ESMO-MCBS Working Group appreciates that it takes time to adopt the SPIRIT-PRO, CONSORT-PRO, and SISAQOL guidelines, published between 2013 and 2020, in study protocols and reports. It acknowledges that clinical trials incorporating QoL endpoints until now were not designed to meet these criteria which are the basis of the ESMO-MCBS QoL checklist. Consequently, the ESMO-MCBS Working Group plans for a stepwise implementation plan for its checklist criteria with a transition period during which not all items of the ESMO-MCBS QoL checklist will have to be met. Clinical trials published until January 2025 that meet the prerequisites and score at least two out of four items on the QoL checklist will be eligible for ESMO-MCBS grading. Clinical trials published thereafter will have to meet the prerequisites and score positive on all four items. If QoL analysis and reporting does not meet the standards defined by the prerequisites or the checklist items, this will be annotated on the ESMO-MCBS Scorecard. The results of QoL studies not showing benefit will be documented as ‘no QoL benefit observed’. However, the checklist will not be applied retroactively to studies that already have received a final score.

A limitation of the four-item checklist is that it does not cover all aspects of the design, analysis, and reporting of QoL research. This was done with the intention to create a pragmatic, user-friendly tool for use in the context of ESMO-MCBS. Furthermore, QoL research is rapidly evolving and we anticipate that the QoL checklist will be revised as standards for QoL research develop. Much anticipated in this regard are the recommendations that will be generated for PRO analysis in clinical cancer trials by the international multidisciplinary consortium SISAQOL-IMI. Once available, these recommendations will be used to inform future refinements of the checklist. For example, the checklist item on compliance rates now relies on the expert opinion of the reviewer on what should be considered a ‘high rate’, because there is no general agreed acceptance threshold for missing data. This is related to the finding that the effect of missing data on bias and power is dependent on several factors, including sample size, disease stage, and missing data mechanism.⁶

Similarly, there is currently no international established standard for a minimal clinically important difference for QoL improvement or deterioration. Several initiatives to define minimum important differences for specific instruments have been published, but thresholds differ by the method that was used, by the direction of change, by domain, and by tumour type.⁴⁰⁻⁴² Therefore, checklist item 4 regarding clinical relevance asks whether a threshold for clinical relevance was pre-specified and taken into account rather than asking for a minimum percentage improvement. ‘Clinically Meaningful Change’ is one of the work packages of SISAQOL-IMI, and if a consensus is reached on a definition, this will be incorporated into the next version of the checklist.

Finally, the QoL checklist has not been validated in single-arm studies. Currently, there is no consensus on whether QoL data from single-arm studies can be used to make conclusions on clinical benefit from medicines, because an improvement in QoL may not necessarily be attributable to the treatment. However, also ‘Single-Arm Studies’ is a topic that will be addressed by SISAQOL-IMI and will be part of future refinement of the checklist.

In summary, implementing this QoL checklist will facilitate objective and transparent decision making on credentialing QoL research within the ESMO-MCBS scoring process. To facilitate accurate QoL scoring, the ESMO-MCBS Working Group encourages timely reporting of all QoL results, including negative studies, according to existing guidelines for QoL research.⁴⁻⁶ This can be either in a separate publication within a reasonable time, or in an extensive data supplement. We hope and anticipate that this initiative will promote greater methodological rigour in designing, implementing, and reporting studies that include QoL as an endpoint.

ACKNOWLEDGEMENTS

The authors acknowledge ESMO and EORTC for making it possible to do this work without external funding. The authors sincerely thank the ESMO leadership for their invaluable support.

FUNDING

No external funding has been received for the preparation of this checklist.

DISCLOSURE

SFO reports research grants from Novartis and Celldex Therapeutics and consultancy fees from BMS (paid to the institution). EGEDV reports an advisory role at Daiichi Sankyo, NSABP, and Sanofi (paid to the institution), and research funding from Amgen, AstraZeneca, Bayer, Chugai Pharma, Crescendo, CytomX Therapeutics, G1 Therapeutics, Genentech, Nordic Nanovector, Radius Health, Regeneron, Roche, Servier, and Synthon (paid to the institution). BG reports receiving consulting fees from Vivio Health. BK reports honoraria for lectures by Ipsen, Novartis, and MSD. JB reports grants, personal fees, and non-financial support from Ipsen, personal fees and non-financial support from Pfizer, non-financial support from AAA, personal fees and non-financial support from Novartis, non-financial support from Nanostring, non-financial support from Roche, grants and personal fees from Servier, and personal fees from Nutricia outside the submitted work. GP received institutional financial support for advisory board/consultancy from Roche, Amgen, Merck, MSD, BMS, and institutional support for clinical trials or contracted research from Amgen, Roche, AstraZeneca, Pfizer, Merck, BMS, MSD, Novartis, Lilly. MPi reports a Scientific Board Member at Oncolytics, consultancy fees from AstraZeneca, Camel-IDS, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Pfizer, Roche-Genentech, Seattle Genetics, Immutep, Seagen, NBE

Therapeutics, Frame Therapeutics and research grants from AstraZeneca, Immunomedics, Lilly, Menarini, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, Synthon (paid to the institution). All other authors have declared no conflicts of interest.

REFERENCES

- Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). *Ann Oncol*. 2015;26:1547-1573.
- ESMO. ESMO-MCBS Scorecards. Available at <https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards>. Accessed August 23, 2021.
- Cherny NI, Dafni U, Bogaerts J, et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. *Ann Oncol*. 2017;28:2340-2366.
- Calvert M, Kyte D, Mercieca-Bebber R, et al. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols. The SPIRIT-PRO extension. *JAMA*. 2018;319:483-494.
- Calvert M, Blazeby J, Altman DG, et al. Reporting of patient-reported outcomes in randomized trials. The CONSORT PRO extension. *JAMA*. 2013;309:814-822.
- Coens C, Pe M, Dueck AC, et al. International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomized controlled trials: recommendations of the SISAQOL Consortium. *Lancet Oncol*. 2020;21:e83-e96.
- Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. *Lancet*. 2017;389:917-929.
- Shaw AT, Kim TM, Crino L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol*. 2017;18:874-886.
- Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. *J Clin Oncol*. 2013;31:3791-3799.
- Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med*. 2012;367:1783-1791.
- Welslau M, Dieras V, Sohn JH, et al. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. *Cancer*. 2014;120:642-651.
- Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol*. 2016;17:425-439.
- Harbeck N, Lyer S, Turner N, et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. *Ann Oncol*. 2016;27:1047-1054.
- Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med*. 2011;364:1817-1825.
- Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. *J Clin Oncol*. 2014;32:1302-1308.
- Stockler MR, Hilpert F, Friedlander M, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab containing therapy for platinum-resistant ovarian cancer. *J Clin Oncol*. 2014;32:1309-1316.
- Sequist LV, Yang JC-H, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. *J Clin Oncol*. 2013;31:3327-3334.

18. Yang JC-H, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. *J Clin Oncol*. 2013;31:3342-3350.
19. Shaw AT, Kim D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med*. 2013;368:2385-2394.
20. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med*. 2014;371:2167-2177.
21. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med*. 2010;363:733-742.
22. Soria J-C, Felip E, Cobo M, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. *Lancet Oncol*. 2015;16:897-907.
23. Felip E, Hirsh V, Popat S, et al. Symptom and quality of life improvement in LUX-Lung 8, an open-label phase III study of second-line afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung after first-line platinum-based chemotherapy. *Clin Lung Cancer*. 2018;19:74-83.e11.
24. Hauschild A, Grob J-J, Demidov LV, et al. Dabrafenib in BRAF mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *Lancet*. 2012;380:358-365.
25. Grob J-J, Amonkar M, Martin-Algarra S, et al. Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality of life analyses of the BREAK-3 study comparing dabrafenib with DTIC. *Ann Oncol*. 2014;25:1428-1436.
26. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med*. 2013;369:213-223.
27. Nilsson S, Cislo P, Sartor O, et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. *Ann Oncol*. 2016;27:868-874.
28. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med*. 2012;367:1187-1197.
29. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med*. 2004;351:1502-1512.
30. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *N Engl J Med*. 2007;356:115-124.
31. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. *J Clin Oncol*. 2009;27:3584-3590.
32. Cella D, Li JZ, Cappelleri JC, et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. *J Clin Oncol*. 2008;26:3763-3769.
33. Fayers PM, Aaronson NK, Bjordal K, et al. *The EORTC QLQ-C30 Scoring Manual*. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer. 2001. Available at <https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf>. Accessed October 15, 2022.
34. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med*. 2014;371:424-433.
35. Loriot Y, Miller K, Sternberg CN, et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. *Lancet Oncol*. 2015;16:509-521.
36. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. *N Engl J Med*. 2012;367:107-114.
37. Schadendorf D, Amonkar M, Milhem M, et al. Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. *Ann Oncol*. 2014;25:700-706.
38. Pe M, Dorme L, Coens C, et al. Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. *Lancet Oncol*. 2018;19:e459-e469.
39. Mercieca-Bebber R, Friedlander M, Calvert M, et al. A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomized controlled trials: implications for generalisability and clinical practice. *J Patient Rep Outcomes*. 2017;1:5.
40. Mouelhi Y, Jouve E, Castelli C, et al. How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods. *Health Qual Life Outcomes*. 2020;18:136.
41. Musoro JZ, Coens C, Fiteni F, et al. Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced breast cancer. *JNCI Cancer Spectr*. 2019;3:pkz037.
42. Musoro JZ, Coens C, Singer S, et al. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer. *Head Neck*. 2020;42:3141-3152.